We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Agreement to Commercialize CRISPR Tools and Reagents


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Agreement to Commercialize CRISPR Tools and Reagents"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, has signed an agreement with New England Biolabs (NEB®), granting NEB rights to sell CRISPR/Cas9 tools and reagents.

NEB offers recombinant and native enzymes for genomic research and aims to continue expanding its product offerings into new areas of research, including genome editing. As a provider of CRISPR/Cas9 reagents and tools, NEB’s license from ERS Genomics expands the Company’s rights to use and sell these technologies.

ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational IP covering CRISPR/Cas9. Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents and genetically modified cell lines and organisms. 


Advertisement